MC
NKTR icon

Miles Capital’s Nektar Therapeutics NKTR Stock Holding History

Miles Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-377
Closed -$601K – 207
2018
Q1 		$601K Sell
377
-182
-33% -$234K 0.33% 60
2017
Q4 		$501K Sell
559
-5
-0.9% -$2.96K 0.29% 62
2017
Q3 		$203K Buy
+564
New +$176K 0.12% 170
2017
Q2 		– Sell
-579
Closed -$204K – 226
2017
Q1 		$204K Buy
+579
New +$130K 0.11% 187

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Miles Capital's NKTR Position: Q2 2018 in Review

Miles Capital sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 377 shares — an estimated $601K sold.

Miles Capital first reported a position in NKTR in Q1 2017 and held it in 4 quarters. The position peaked at $601K in Q1 2018. 379 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

  • Miles Capital reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Miles Capital sold 377 Nektar Therapeutics shares in Q2 2018, an estimated $601K.
  • Miles Capital first reported a position in Nektar Therapeutics in Q1 2017 and held it in 4 quarters.
  • Miles Capital's Nektar Therapeutics position peaked at $601K in Q1 2018.
  • 379 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Miles Capital's 13F filing for Q2 2018, filed 14 Aug 2018.